Pharmaceuticals - Australia

Australia

The projected revenue in the Pharmaceuticals market in Australia is estimated to reach €9.27bn in 2024.
Among the various markets, the largest market is Oncology Drugs, which is projected to have a market volume of €1.67bn in 2024.
The revenue in the Pharmaceuticals market is expected to grow at an annual rate of 4.86% from 2024 to 2029, resulting in a market volume of €11.75bn by 2029.
In a global comparison, United States is expected to generate the highest revenue, with €578.50bn in 2024.
Australia's pharmaceutical market is experiencing a surge in demand for innovative and personalized medications.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Next generation therapies are also part of the Pharmaceuticals market and include gene therapy, cell therapy, and nucleic acid therapy. Cell therapies involve the use of living cells to replace or repair damaged tissues within the patient's body, or to modify cells to perform specific functions. Gene therapies focus on altering a patient’s genetic material to regulate the production of certain proteins. Nucleic acid therapies use short strands of DNA or RNA to inhibit the production of harmful proteins associated with diseases and promote the generation of therapeutic proteins. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The demand for Pharmaceuticals in Australia has been on a steady rise in recent years.

Customer preferences: Customers in Australia have shown a growing interest in natural and organic products. This has led to an increase in demand for natural remedies and supplements. Additionally, the aging population in Australia has resulted in a rise in demand for medications to treat chronic conditions such as diabetes, cardiovascular disease, and arthritis.

Trends in the market: One of the major trends in the pharmaceutical market in Australia is the growing popularity of e-pharmacies. Customers are increasingly turning to online pharmacies for convenience and accessibility. Another trend is the rise of biosimilars, which are becoming more widely accepted as a cost-effective alternative to branded biologic drugs. Finally, there has been a shift towards personalized medicine, with a growing number of medications being tailored to individual patients based on their genetic makeup.

Local special circumstances: The Australian government heavily regulates the pharmaceutical industry, which has resulted in a relatively stable market. However, the government's Pharmaceutical Benefits Scheme (PBS) has been under pressure due to rising healthcare costs. This has led to increased scrutiny of the prices of pharmaceuticals and a push towards greater use of generics and biosimilars.

Underlying macroeconomic factors: The Australian economy has remained relatively stable in recent years, with low unemployment and steady GDP growth. However, the country's aging population is putting pressure on the healthcare system, which is leading to a greater focus on preventative medicine and chronic disease management. Additionally, the COVID-19 pandemic has highlighted the importance of a robust healthcare system, which may lead to increased investment in the pharmaceutical industry in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.